By Fineline Cube 
Full‑Life Technologies, a global radiotherapeutics integrator, announced today the successful completion of $77 million in financing, comprising $49.8 million in Series C equity and $27 million in debt. The capital raise is aimed at accelerating the development of the company’s radiopharmaceutical pipeline and expanding its manufacturing footprint in Belgium.
Investor Commitments
- Series C Equity – Led by Junson Capital, the round attracted new investors Lapam Capital, Plaisance, TruMed Investment and other prominent syndicate members.
- Existing Shareholders – Current stakeholders Chengwei Capital, Gordian Ventures, HSG, Prosperity7, Summer Capital and additional respected investors reaffirmed their support, underscoring confidence in Full‑Life’s growth trajectory.
Strategic Impact
- Pipeline Advancement – The infusion will fund late‑stage development of the company’s radiopharmaceutical offerings, targeting unmet clinical needs across oncology and diagnostic imaging.
- Manufacturing Expansion – Capital will be deployed to scale production capacity in Belgium, positioning Full‑Life to meet global demand and secure regulatory approval for its next‑generation therapeutics.
- Full‑Value‑Chain Vision – With operations spanning Belgium, Germany, and China, Full‑Life remains committed to owning research, development, production, and commercialization, ensuring end‑to‑end control and rapid patient access.
Market Context
The radiopharmaceutical market is poised for significant growth as personalized oncology therapies gain traction. Full‑Life’s integrated model places it in a strong position to capture value from both therapeutic and diagnostic segments, while the recent funding round enhances its competitive edge against larger incumbents and emerging start‑ups.-Fineline Info & Tech